Tagged with EU

Europe The Women’s Brain Foundation, formerly the Women’s Brain Project, has evolved into a fully-fledged foundation dedicated to advancing research in gender precision medicine with a strong focus on brain health. CEO pro-bono Dr Antonella Santuccione Chadha comments on the organisation’s newly extended global reach, progress in understanding the link between…

CEE A roundup of some of the top news coming out of the Central and Eastern European (CEE) region’s pharma industry, including Poland’s first draft of a national critical medicines list; Polpharma’s acquistion of the dermatological firm Ziołolek; Sopharma’s sale of its logistics unit, Farmalogistika; Horus Pharma’s significant stake in Romania’s…

Europe Jazz Pharmaceuticals is about to open a new chapter in its history. As long-standing CEO and co-founder Bruce Cozadd prepares to step down for retirement, the neuroscience and oncology-focused company begins its search for a new leader and gets ready to commercialize recently FDA-approved HER2-targeted bispecific antibody, Ziihera.    End…

Switzerland Switzerland’s healthcare system is globally renowned. It leads the world on metrics such as infrastructure, medical advances, and patient freedom to choose healthcare services, and ranks 1st in US thinktank FREOPP’s 2022 World Index of Healthcare Innovation. However, it lags in one key area: digitalisation. On that front, Switzerland has…

Switzerland Although the global biotech sector is currently struggling with equity and debt financing, Swiss biotech is on the up. 2023 saw the Swiss biotech sector hit record revenues of CHF 7.3 billion (EUR 7.8 billion) with capital investments surpassing CHF 2 billion. While funding inflows still did not reach the…

China Vincent Chan, VP and GM of bioMérieux Greater China, shares insights into how the microbiology diagnostics company’s presence has evolved in China over the course of 30 years to today serve some 4,000 hospitals across the country. He walks us through the government measures that have prioritized microbiology testing to…

Switzerland Dominik Escher, Managing Partner of Pureos Bioventures explores the firm’s strategic focus on drug development, particularly in biologics and antibody-based therapeutics. With a keen emphasis on the Swiss biotech ecosystem, Escher discusses the firm’s investment approach and its commitment to fostering innovation in Europe and beyond.   Swiss biotech stands…

Switzerland Emanuele Ostuni, CEO of ARTBIO, delves into the company’s innovative approach to radioligand therapies, focusing on its potential to replace chemotherapy and provide more effective treatment options for patients. Ostuni emphasizes the company’s commitment to precision oncology, with a strong team spread across Switzerland, Norway, USA, and the UK.  …

France A roundup of the top stories coming out of France’s pharma industry, including Sanofi’s consumer health unit spinout and EUR 40 million investment in antibody bioproduction; the French govenment’s unprecedented deal with Upsa; the Health Minister’s plans to lower the national social security system’s reimbursement of drugs; Servier’s newfound willingness…

Switzerland Marianthi Psaha, President, Head of EMEA for Santen, discusses the company’s journey towards becoming a specialized leader in ophthalmology—highlighting how digital transformation, innovation in myopia treatment, and strategic partnerships are reshaping its impact on eye health across Europe. Psaha delves into the challenges of building awareness of the area’s importance…

Global With the emergence of GLP-1 RA therapies the obesity drug market has taken off and stands to be worth some USD 125.3 billion by 2033. Eli Lilly and Novo Nordisk may lead the charge, but other contenders are looking to get a piece of this lucrative market as the two…

Switzerland Europe and Canada (EUCAN) have an essential role in Takeda’s global mission to advance healthcare innovation. Ricardo Marek, President of Takeda’s EUCAN division, discusses the operational and regulatory challenges, the importance of Switzerland as a strategic base, and Takeda’s post-Shire acquisition growth strategy.   Europe is central not just as…